Literature DB >> 29253622

Regional point prevalence study of healthcare-associated infections and antimicrobial use in acute care hospitals in Liguria, Italy.

C Sticchi1, M Alberti2, S Artioli3, M Assensi4, I Baldelli5, A Battistini6, S Boni3, G Cassola7, Elio Castagnola8, M Cattaneo9, N Cenderello10, M L Cristina10, A M De Mite9, P Fabbri10, F Federa9, D R Giacobbe11, D La Masa5, C Lorusso12, K Marioni3, V M Masi2, B Mentore12, S Montoro4, A Orsi6, D Raiteri13, R Riente14, I Samengo12, C Viscoli11, R Carloni15.   

Abstract

BACKGROUND: Given the importance of monitoring healthcare-associated infections (HCAIs) and the consumption of antibiotics, a regional point prevalence survey was conducted in Liguria between March and April 2016. AIM: To measure the overall prevalence of HCAI and describe the use of antibiotics in all public hospitals.
METHODS: Data on risk factors and use of antibiotics were collected for each hospitalized patient. To define the variables significantly associated with HCAI, univariate and multivariate analyses were conducted. Standardized infection ratio and standardized antimicrobial use ratio were measured for each participating hospital.
FINDINGS: A total of 3647 patients were enrolled. In all, 429 HCAIs were diagnosed in 376 patients, giving a prevalence of HCAI of 10.3%. Respiratory tract (21.7%) and urinary tract (20%) were the most frequent sites of infection. High rates of meticillin-resistant Staphylococcus aureus (47.4%) and Enterobacteriaceae resistant to carbapenems (26.3%) were isolated. Forty-six percent of patients received at least one antibiotic. Combinations of penicillins including β-lactamase inhibitors (24.1%) were the most widely used; the main indication (46.7%) was the treatment of a community-acquired infection.
CONCLUSION: There was an increase in HCAI prevalence compared to a similar survey conducted in 2007; however, the performance of overlapping investigations will enable more reliable considerations. Nevertheless, data on antimicrobial resistance and use of antibiotics are consistent with the national trend. Despite methodological limitations, prevalence studies are useful to monitor HCAI over time and encourage greater awareness of the problem by all stakeholders.
Copyright © 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Antimicrobial use; Healthcare-associated infection; Point prevalence study

Mesh:

Substances:

Year:  2017        PMID: 29253622     DOI: 10.1016/j.jhin.2017.12.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  13 in total

1.  Atti Le giornate della ricerca scientificae delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Roma 20-21 dicembre 2019.

Authors: 
Journal:  J Prev Med Hyg       Date:  2020-02-13

2.  Point prevalence surveys of health-care-associated infections: a systematic review.

Authors:  Zikria Saleem; Brian Godman; Mohamed Azmi Hassali; Furqan Khurshid Hashmi; Faiza Azhar; Inayat Ur Rehman
Journal:  Pathog Glob Health       Date:  2019-06-19       Impact factor: 2.894

3.  A multicentre study investigating parameters which influence direct bacterial identification from urine.

Authors:  Yuliya Zboromyrska; Jordi Bosch; Jesus Aramburu; Juan Cuadros; Carlos García-Riestra; Julia Guzmán-Puche; Carmen Liébana Martos; Elena Loza; María Muñoz-Algarra; Carlos Ruiz de Alegría; Victoria Sánchez-Hellín; Jordi Vila
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

4.  Estimating global trends in total and childhood antibiotic consumption, 2011-2015.

Authors:  Charlotte Jackson; Yingfen Hsia; Julia A Bielicki; Sally Ellis; Peter Stephens; Ian C K Wong; Mike Sharland
Journal:  BMJ Glob Health       Date:  2019-02-27

5.  Is Post-Reprocessing Microbiological Surveillance of Duodenoscopes Effective in Reducing the Potential Risk in Transmitting Pathogens?

Authors:  Maria Luisa Cristina; Marina Sartini; Elisa Schinca; Gianluca Ottria; Chiara Dupont; Palmira Bova; Gianni Coccia; Beatrice Casini; Anna Maria Spagnolo
Journal:  Int J Environ Res Public Health       Date:  2019-12-24       Impact factor: 3.390

6.  Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship.

Authors:  Kathrin Rothe; Susanne Feihl; Jochen Schneider; Fabian Wallnöfer; Milena Wurst; Marina Lukas; Matthias Treiber; Tobias Lahmer; Markus Heim; Michael Dommasch; Birgit Waschulzik; Alexander Zink; Christiane Querbach; Dirk H Busch; Roland M Schmid; Gerhard Schneider; Christoph D Spinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-11-02       Impact factor: 3.267

7.  A Six-Year Point Prevalence Survey of Healthcare-Associated Infections in an Italian Teaching Acute Care Hospital.

Authors:  Andrea Gentili; Marcello Di Pumpo; Daniele Ignazio La Milia; Doriana Vallone; Gino Vangi; Maria Incoronata Corbo; Filippo Berloco; Andrea Cambieri; Gianfranco Damiani; Walter Ricciardi; Patrizia Laurenti
Journal:  Int J Environ Res Public Health       Date:  2020-10-22       Impact factor: 3.390

Review 8.  Epidemiology and Prevention of Healthcare-Associated Infections in Geriatric Patients: A Narrative Review.

Authors:  Maria Luisa Cristina; Anna Maria Spagnolo; Luana Giribone; Alice Demartini; Marina Sartini
Journal:  Int J Environ Res Public Health       Date:  2021-05-17       Impact factor: 3.390

9.  Evaluation of bacterial agents isolated from endotracheal aspirate cultures of Covid-19 general intensive care patients and their antibiotic resistance profiles compared to pre-pandemic conditions.

Authors:  Yasemin Genç Bahçe; Ömer Acer; Osman Özüdoğru
Journal:  Microb Pathog       Date:  2022-01-15       Impact factor: 3.738

10.  Analysis of Continuous Prevalence Survey of Healthcare-Associated Infections Based on the Real-Time Monitoring System in 2018 in Shandong in China.

Authors:  Jian Sun; Wen Qin; Lei Jia; Zhen Sun; Hua Xu; Yiyi Hui; Anman Gu; Weiguang Li
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.